Reminder for Novo Nordisk A/S shareholders: pending class action lawsuit with a lead plaintiff deadline set for September 30, 2025, highlighted by Levi & Korsinsky.
In a significant development, the law firm of Levi & Korsinsky has announced a class action securities lawsuit against Novo Nordisk A/S. The lawsuit, consolidated in a central multidistrict litigation (MDL) in the USA, alleges that the company made materially false and misleading statements concerning its growth potential.
The complaint specifically mentions that Novo understated the potential impact of the personalization exception to the compounded GLP-1 exclusion. It also alleges that defendants overstated the likelihood of patients switching to Novo's branded alternatives and the potential GLP-1 market.
The prosecutor investigating the lawsuit procedure against Novo Nordisk A/S is not explicitly named. However, over 2000 lawsuits in the USA imply that US courts and possibly federal prosecutors or plaintiff attorneys are involved.
The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected between May 7, 2025, and July 28, 2025. Eligibility for compensation does not require serving as a lead plaintiff.
Following this news, the price of Novo's common stock declined dramatically, from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, a decline of about 21.83% in a single day.
On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down to lower growth expectations for the second half of 2025 for both Wegovy and Ozempic due to the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition.
Levi & Korsinsky, LLP, with a team of over 70 employees, has a track record of winning high-stakes cases and has extensive expertise in complex securities litigation. The firm has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven years in a row.
Investors who were adversely affected are encouraged to visit zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=168147&wire=3 for more information and to be contacted by a member of the team. Investors can also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500 for more information.
Notably, there are no out-of-pocket costs or fees for class members in the lawsuit against Novo Nordisk A/S. The deadline for investors to request appointment as lead plaintiff is September 30, 2025.
For more details about Levi & Korsinsky, LLP, including contact information, visit their website at www.zlk.com.
Read also:
- Strategizing the Integration of Digital Menus as a Core Element in Business Operations
- Financial Actions of BlockDAG Following Inter and Borussia Agreements: Anticipating Future Steps
- International powers, including France, Germany, and the UK, advocate for the reinstatement of sanctions against Iran.
- Companies urged to combat employee resignation crisis, as per findings from the Addeco Group
